Philadelphia University + Thomas Jefferson University

Rolling Deadlines

ORGANIZATION / WEBSITE SPECIALTY
AREA
PURPOSE AWARD / DEADLINE
National Cancer Institute
Go to site...<
Imaging and Biomarkers for Early Detection of Aggressive Cancer
The purpose of this Funding Opportunity Announcement (FOA) is to: (i) invite researchers to submit collaborative research project (U01) applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach, and (ii) establish a Consortium for Imaging and Biomarkers (CIB) to perform collaborative studies, exchange information, share knowledge and leverage common resources.
Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: July 11, 2016; December 14, 2016; July 10, 2017; December 11, 2017; July 10, 2018; December 11, 2018

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...
Stroke Prevention, Treatment, and Recovery
This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery.  Successful applicants will collaborate and conduct the trial within the NIH StrokeNet.  Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support.  The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program.  Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA.
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum requested project period cannot exceed 5 years but the actual funded project period is dependent on reaching specific milestones as described in this FOA.
Date: July 11, 2017 and then Standard dates apply  by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Radiation Therapy, Synthetic Chemotherapy, Molecularly Targeted Drugs The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NCI intends to support three new U01 awards in total as part of this PCRTC consortium starting FY 2016-18. The FOA may be terminated early if these are awarded prior to its expiration. Application budgets must not exceed $450,000 per year in direct costs. The maximum project period is five years.

Date: July 14, 2016; December 14, 2016; July 14, 2017; December 14, 2017, by 5:00 P.M.

National Center for Advancing Translational Sciences (NCATS)

Go to site...

Psychotic Disorders, Coordinated Specialty Care Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning grant applications that (1) identify a baseline rate of DUP in community settings that include CSC programs; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. 

The NIMH intends to commit approximately $3,000,000 in FY 2017 to fund between 4 and 6 grants submitted to this FOA and the companion FOA PAR-16-265. Direct costs are limited to $450,000 over the R34 project period, with no more than $225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this FOA may not exceed 3 years.

Date: July 19, 2016; November 18, 2016; March 17, 2017; July 18, 2017; November 17, 2017; March 19, 2018; July 18, 2018; November 19, 2018; March 19, 2019, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Psychotic Disorders, Coordinated Specialty Care Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning grant applications that (1) identify a baseline rate of DUP in community settings that include CSC programs; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. 

The NIMH intends to commit approximately $3,000,000 in FY 2017 to fund between 4 and 6 grants submitted to this FOA and the companion FOA PAR-16-265. Direct costs are limited to $450,000 over the R34 project period, with no more than $225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this FOA may not exceed 3 years.

Date: July 19, 2016; November 18, 2016; March 17, 2017; July 18, 2017; November 17, 2017; March 19, 2018; July 18, 2018; November 19, 2018; March 19, 2019, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Cancer This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).    The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

National Institute on Drug Abuse (NIDA)

Go to site...

Substance Abuse and Addiction The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for support of non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Although the size of the award may vary with the scope of the research education program proposed, it is expected that applications will not exceed $350,000 in total direct costs annually. The scope of the proposed project should determine the project period. The total project period, however, may not exceed 5 years.

Date: July 19, 2016; November 22, 2016; March 22, 2017; July 19, 2017; November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM

Fogarty International Center (FIC), National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Infectious Disease Research This Funding Opportunity Announcement (FOA) encourages applications for the Global Infectious Disease (GID) Research Training Program from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of an LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applications budgets are limited to $230,000 per year for new awards and $276,000 per year for renewal awards (total direct costs). The maximum project period is up to 5 years.

Date:July 21, 2016; July 21, 2017;July 20, 2018, by 5:00 PM

Fogarty International Center (FIC)

Go to site...

Infectious Disease Research This Funding Opportunity Announcement (FOA) encourages applications for a planning grant from institutions in low- and middle-income countries (LMICs) to design a Global Infectious Disease (GID) Research Training Program in collaboration with U.S. institutions. The application should propose a collaborative process to design a training program that will strengthen the capacity of the LMIC institution to conduct infectious disease research. Planning grants should describe a detailed vision for a research-training program that focuses on a major endemic or life-threatening emerging infectious disease, neglected tropical disease, infections that frequently occur as a co-infection in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.   

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applications budgets are limited to $46,000 (total direct costs). The maximum project period is 1 year.

Date: July 27, 2017; July 26, 2018; July 25, 2019, by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Go to site...

Diabetes, Digestive Disease, Kidney Disease The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK.   The interdisciplinary approach encouraged by this FOA is envisioned to generate a community research resource for the broader community, which may include discovery-based or hypothesis-generating science.   The interdisciplinary research team should be able to provide an integrative plan of working together to effectively address the complex challenge at hand.   This program will support research projects that accelerate critical breakthroughs, early and applied research on cutting-edge technologies, and new approaches to improve the synergy and interactions among multi- and interdisciplinary research teams, including sharing of data and other resources to further advance research in this area. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment and prevention of diseases within the mission of NIDDK.  

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total annual cost for individual awards is expected to vary, depending on the scope of the project and the number of participating institutions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years. 

Date: June 1, 2016; November 1, 2016; June 1, 2017; November 1, 2017; June 1, 2018; November 1, 2018, by 5:00 P.M.

National Cancer Institute (NCI)

Go to site...

Career Development-Clinical Trials Researchers This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).      

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to $50,000 in the initial year of new (Type 1) programs and may be used for curriculum planning and development, advertising and recruiting of the first class of Scholars. K12 scholars will begin work in the second year of the grant, where costs are limited to $750,000 in direct costs annually. For renewal (Type 2) applications, the program may request up to $750,000 in direct costs annually in each of the 5 years. The project award duration for this funding opportunity may not exceed 5 years.

Date: June 15, 2016; June 15, 2017; June 15, 2018, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Cancer Biology, Oncology The National Cancer Institute (NCI) is sponsoring a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers (RFA-CA-15-014), a U24 CSBC Coordinating Center (RFA-CA-15-015) and, through this FOA, well-defined, discrete and circumscribed Research Projects addressing emerging problems in cancer. The CSBC initiative aims to address challenges in cancer research through the use of experimental biology or population science combined with in silico modeling, multi-dimensional data analysis, and systems engineering. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment. CSBC Research Projects are expected to involve interdisciplinary teams of physical scientists (e.g., engineers, chemists, computer scientists, mathematicians, physicists, population scientists, statisticians, epidemiologists) and cancer researchers (e.g., cancer biologists, oncologists, pathologists and clinicians in relevant disciplines) who collaborate to advance our understanding of cancer biology and oncology. CSBC Research Projects proposed in response to this FOA must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.  

Date: June 24, 2016; November 18, 2016; June 23, 2017; November 24, 2017; June 22, 2018; November 23, 2018, by 5:00 P.M.  

Center for Food Safety and Applied Nutrition (CFSAN), Office of Regulatory Affairs (ORA)

Go to site...

Food Safety The overall purpose of this FOA is to establish or enhance State and Territory Produce Safety Programs to encourage the safe production of fresh fruits and vegetables and to promote compliance with the requirements of FDA’s Regulation “Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption” (commonly referred to as the Produce Safety Rule). Improving produce safety will help Federal, State, and Territory authorities better direct their food safety and regulatory activities at reducing foodborne illness hazards.

The number of awards and final funding levels is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations, availability of funding and awardee performance. FDA/ORA intends to fund up to $19 million, for fiscal year 2016 in support of this grant program. It is anticipated that up to fifty five (55) awards will be made, not to exceed $1.1 million in total costs (direct plus indirect), per award. The scope of the proposed project should determine the project period. The maximum project period is five (5) years.

Date: June 3, 2016 by 11:59 PM Eastern Time. April 3, 2017, 2018, 2019, by 11:59 PM Eastern Time.

National Institute of Environmental Health Sciences (NIEHS)

Go to site...

Environmental Health Research This funding opportunity announcement (FOA) is intended to support environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data.  The primary motivation of the FOA is to understand the consequences of natural and man-made disasters or emerging environmental public health threats in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding (substantially shorter than the typical NIH grant review/award cycle) in order for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.   

NIEHS intends to commit $800,000 per year in fiscal years 2016, 2017, 2018, and 2019 to fund 3-4 awards each year. The combined budget for direct costs for the 2-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The maximum period may not exceed 2 years.

Date: June 3, 2016,  July 1, 2016, August 1, 2016, September 1, 2016, October 3, 2016, November 1, 2016, December 1, 2016, January 3, 2017, February 1, 2017, March 1, 2017, April 3, 2017, May 1, 2017, June1, 2017, July 3, 2017, August 1, 2017, September 1, 2017, October 2, 2017, November 1, 2017, December 1, 2017, January 2, 2018, February 1, 2018, March 1, 2018, April 2, 2018, May 1, 2018, June 1, 2018, July 2, 2018, August 1, 2018, September 4, 2018, October 1, 2018, November 1, 2018, December 3, 2018, January 2, 2019, February 1, 2019, March 1, 2019, April 1, 2019, May 1, 2019, June 1, 2019, by 5:00 PM local

National Cancer Institute (NCI)

Go to site...

Pediatric Cancer Research The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI’s Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI’s Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list.

Date: June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Pediatric Cancer Research The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI’s Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: June 5, 2016; June 5, 2017; June 5, 2018, by 5:00 P.M.June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Spermatogenic Stem Cell (SSC) Biology The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of spermatogenic stem cell (SSC) biology.  The overarching goal is to increase the chances that couples may have biological offspring without using conventional assisted reproductive modalities (i.e., IVF, ICSI).  A focal point of the initiative is on the development of new techniques to culture and expand these cells over an extended period of time.  Another area of study includes methods to eliminate malignant cells from SSC cultures following chemotherapy/radiation treatment. Also, spermatogenic stem cells from human adults could have a major impact on drug development and toxicity testing as animal-based systems do not sufficiently mirror the situation in humans.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $300,000/yr (direct costs) and should reflect the actual needs of the proposed project. The maximum period of support is three years.

Date: June 5, 2016; June 5, 2017; June 5, 2018, by 5:00 P.M.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR)

Go to site...

Embryonic Lethal Knockout (KO) Mouse Strains  The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.  The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years.  Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains.  About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable.  A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.  The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Budgets with direct costs of up to $499,999 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: June 5, 2017 (new) and July 5, 2017 (renewal, resubmission, revision); October 5, 2017 (new) and November 5, 2017 (renewal, resubmission, revision); June 5, 2018 (new) and July 5, 2018 (renewal, resubmission, revision); October 5, 2018 (new) and November 5, 2018 (renewal, resubmission, revision); June 5, 2019 (new) and July 5, 2019 (renewal, resubmission, revision); October 5, 2019 (new) and November 5, 2019 (renewal, resubmission, revision), by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Mental Health (NIMH)

Go to site...

HIV Prevention The purpose of this Funding Opportunity Announcement (FOA) is to promote multidisciplinary research programs that (1) devise optimal HIV prevention packages (combination interventions) for specific populations and (2) perform feasibility and acceptability studies to demonstrate that the proposed prevention package is acceptable to the target population and the study design is appropriate and feasible. This FOA is intended to encourage collaborations between behavioral and biomedical clinical specialists, epidemiologists, mathematical modelers, and clinical research specialists.  

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.  

Date: 

June 7, 2016; June 7, 2017; June 7, 2018, by 5:00 P.M.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Go to site...

Clinical Interventional Trials relevant to NIAMS mission This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to permit the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant is recommended prior to submission of an application through a U01 clinical trial implementation application that will support the actual implementation and conduct of the study.  The planning should be intended to support trials that are hypothesis-driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $300,000 in direct costs over a period of two years.  The amount of support requested should reflect the actual needs of the proposed project. The maximum project period is two years.

Date: March 1, 2017; July 3, 2017; November 1, 2017; March 2, 2018; July 2, 2018; November 1, 2018; March 1, 2019; July 1, 2019; November 1, 2019, by 5:00 PM

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Go to site...

Clinical Interventional Trials relevant to NIAMS mission This Funding Opportunity Announcement (FOA) invites cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases).  Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2).  Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a R34.  The NIAMS expects such trials to be hypothesis driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The project period may not exceed five years.

Date: March 1, 2017; July 3, 2017; November 1, 2017; March 2, 2018; July 2, 2018; November 1, 2018; March 1, 2019; July 1, 2019;November 1, 2019, by 5:00 PM

Office of Regulatory Affairs (ORA)

Go to site...

State Manufactured Food Regulatory Programs The intended outcome of this FOA is to advance efforts for a nationally integrated food safety system (IFSS) by supporting Manufactured Food Regulatory Program Standards (MFRPS), Rapid Response Teams (RRT) and Food Protection Task Force (FPTF) programs, as well as special projects. For the purposes of this FOA, the term State encompasses all eligible organizations as defined in Section 3. 

 

Date: March 1, 2018, by 11:59 PM Eastern Time

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

AIDS Prophylactic Vaccine Discovery Research The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive modeling of vaccine concepts in non-human primates may be included.

NIH intends to fund an estimate of 1-2 awards, corresponding to a total of $4M, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are limited to $2.5M/year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Date: March 13, 2018; March 13, 2019; March 13, 2020 , by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Go to site...

Digestive and Liver Diseases This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.  The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases.  DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.  Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

NIH intends to fund an estimate of 1-2 awards, corresponding to a total of $4M, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are limited to $2.5M/year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.NIDDK intends to commit $2.4 million in FY 2018 to fund 2 awards and $3.6 million in FY 2019 to fund 3 awards. Application budgets are limited to $750,000 direct costs per year, exclusive of any consortium/contractual facilities and administrative (F&A) costs but need to reflect the actual needs of the proposed project. The project period for an application submitted to this funding opportunity may not exceed five years.

Date: March 13, 2018; March 13, 2019; March 13, 2020 , by 5:00 PM

Fogarty International Center (FIC)

Go to site...

Non-Communicable Diseases and Disorders (NCDs) in LMIC Populations This  Funding Opportunity Announcement (FOA) for research training program planning invites submissions from low- and middle-income country (LMIC) institution(s) with existing research and research training capacity in chronic, non-communicable diseases and disorders (NCDs). These institutions must propose to assess needs and develop a plan for a research training program within the LMIC(s) that will further strengthen the capacity of LMIC individuals, institution(s) and country(ies) to identify NCD priorities and conduct NCD research across the lifespan. The application from the LMIC institution(s) may include collaboration with United States (U.S) institutions and other LMIC institutions as justified and appropriate.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited $46,000 (total direct costs) The maximum project period is 1 year.

Date: March 14, 2017 and June 1, 2018, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)

Go to site...

HIV Phylodynamics The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research collaborations to study and optimize approaches using phylodynamic analyses of HIV genotyping databases to monitor HIV transmission networks in near real-time. The long-range goal is to leverage existing databases and support innovations in HIV phylodynamics to better inform testing, treatment, and prevention efforts.

NIH intends to fund an estimate of 4-7 awards, corresponding to a total of $4.39 M, for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are limited to $499,999 per year in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: March 14, 2017; March 14, 2018; March 14, 2019, by 5:00 PM

National Cancer Institute

Go to site...

Collaborative Partnerships in Cancer Research (P20) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for  developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs).

The partner applications, ISUPS and Cancer Center, may request $275,000 in direct costs.  The combined budget of direct costs cannot exceed $275,000.

Date: March 15, 2017; March 15, 2018; March 15, 2019  , by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)

Go to site...

Multipurpose Prevention Technologies (MPT), Pregnancy and HIV Infection The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs.  MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA. 

Issuing IC and partner components intend to commit $4.1 million in FY 2019 to fund 2-3 awards. Application budgets are limited to $800,000 in direct costs per year for the R61 award phase and $1,600,000 in direct costs per year for the R33 award phase. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

Date: March 18, 2016; January 27, 2017; January 29, 2018

National Institute on Aging (NIA), National Institute of Nursing Research (NINR)

Go to site...

Alzheimer's Disease and related Dementias This Funding Opportunity Announcement (FOA) encourages Revision applications from currently active NIA and NINR institutional training grants that propose a new research emphasis on Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) or propose to expand the scope of AD/ADRD research on their existing training grant. The revision should provide for the seamless integration of AD/ADRD into the overall scientific emphasis of the ongoing training program.

NIA intends to commit $1.2 M in FY 2017 to fund 3-5 awards. Application budgets are limited to $300K in direct costs, and should reflect the actual needs of the proposed revision project. Award Project Period: 3-5 years.

Date: March 2, 2017; January 25, 2018; and January 25, 2019, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

Investigator-Initiated Clinical Trials This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The application should propose the developmental work to be performed that would enhance the probability of reaching definitive outcomes in a clinical trial.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

Date: March 24, 2017, July 24, 2017, November 24, 2017, March 23, 2018, July 24, 2018, November 26, 2018, March 25, 2019, July 24, 2019, November 25, 2019, by 5:00 PM

National Institute on Drug Abuse (NIDA)

Go to site...

Medications Development for Substance Use Disorders (SUDs) The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside  organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.  Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process.  Both the project period and budget  of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding.  Project aims can range from the development of a new molecular entity to the expansion of an existing medication’s clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process.  It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets for direct costs may be up to $3,000,000 per year, but need to reflect the actual needs of the proposed project. The maximum period of support is 3 years.

Date: March 27, 2017; July 25, 2017; March 27, 2018; July 25, 2018; March 27, 2019; July 25, 2019, by 5:00

National Institute on Drug Abuse (NIDA)

Go to site...

Medications Development for Substance Use Disorders (SUDs) The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance-Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIH intends to fund an estimate of 2-3 awards per year. Application budgets are limited to $5 million per year for direct costs. The maximum project period is 3 years.

Date: March 27, 2017; July 25, 2017; March 27, 2018; July 25, 2018; March 27, 2019; July 25, 2019, by 5:00

National Eye Institute (NEI)

Go to site...

Visual System Diseases/Disorders In the context of this program, an expert assembles a multi-disciplinary research team that uses an integrative approach to develop rapid and efficient translation of innovative laboratory research findings into therapies, devices or other resources for use by clinicians to treat visual system diseases or disorders. It involves collaborative teams of scientists and clinicians with expertise in multiple disciplines, operating according to a clear leadership plan. Such a collaborative approach is particularly appropriate for research focused on pathways that will likely be targeted by biological intervention, such as gene therapy, cell-based therapy, pharmacological approaches, and the development and use of medical devices. The intention of this program is to make technological, biological and pharmacological resources available to clinicians and their patients. Each project should have a well-defined end-point, achievable within a five-year time frame, of developing a device or treatment for a specific ocular disease. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a device or therapeutic that can be tested in a clinical trial. If successful, a project funded under this program should lead to filing an Investigational New Drug (IND)-directed pharmacological and toxicological study, an Investigational Device Exception (IDE)-directed clinical study, Phase I clinical testing and a subsequent application for a NEI UG1 Clinical Vision Research Grant or a R34 Clinical Study Development Grant.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request up to $1.5 million per year direct costs (exclusive of consortium facilities and administrative costs). The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: March 27, 2017; March 27, 2018; March 27, 2019, by 5:00 PM

NIH Basic Behavioral and Social Science Opportunity Network (OppNet) and its participating Institutes, Centers and Offices: National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), Division of Program Coordination, Planning and Strategic Initiatives,
 Office of Behavioral and Social Sciences Research (OBSSR)

Go to site...

Short-Term Mentored Career Development This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.



Award budgets are composed of salary and other program-related expenses, as described: NIH will contribute up to $80,000 per year toward the salary of the career award recipient. Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. Projects may not exceed $100,000 in total costs. NIH will contribute $20,000 maximum per year toward the research development costs of the award recipient. The total project period may not exceed 1 year.

Date: March 6, 2018, and March 6, 2019, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA), National Institute of General Medical Sciences (NIGMS)

Go to site...

Clinical Trials  This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period of 6 or 7 years.

Date: March 7, 2017; December 7, 2017; March 7, 2018; December 7, 2018; March 7, 2019; December 6, 2019, by 5:00 PM

National Institute of Environmental Health Sciences (NIEHS)

Go to site...

Environmental Health The purpose of the ViCTER program is to foster and promote transdisciplinary collaborations and/or translational research efforts among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers and other individuals with expertise relevant to environmental health who have come together in common interest around a particular environmental stressor(s) of interest.  A key component of the Virtual Consortia Program is the stimulation of innovative and novel cross-disciplinary and/or translational collaborations that can be more difficult to achieve in a typical R01 application, thereby accelerating the public health impact of the research.

NIEHS intends to fund an estimate of 3-4 awards, corresponding to a total of $2,000,000 for each fiscal year, FY2018, FY2019 and FY2020. Application budgets are limited to $300,000 direct cost per year and should reflect the actual needs of the proposed project. Applicants must request support for 2 or 3 years (no partial years), not to exceed the remaining number of years on the parent grant at the time of the earliest start date of the award. The parent grant must be active during the entire project period proposed in the Revision application.

Date: March 7, 2017; March 6, 2018; March 6, 2019, by 5:00 PM

National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD),  Office of Behavioral and Social Sciences Research (OBSSR)

Go to site...

Native American (NA) Health The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. The scope of the proposed project should determine the project period. The total project period may not exceed 2 years.

Date: May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM

National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), Office of Behavioral and Social Sciences Research (OBSSR)

Go to site...

Native American (NA) Health The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years.

Date: May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Mental Health (NIMH)

Go to site...

Monoclonal Antibodies (mAb) or mAb Derivatives, HIV Reservoir This Funding Opportunity Announcement (FOA) encourages applications to support the optimization of monoclonal antibodies (mAb) or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Date: May 16, 2016; January 10, 2017; May 9, 2017; January 9, 2018; May 8, 2018; January 9, 2019, by 5:00 P.M.

National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)

Go to site...

HIV, Biomedical The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research that addresses one or both of the following objectives: Devise optimal strategies to improve the identification of persons unaware of their HIV-1 infection and successfully link them to HIV testing, treatment, and prevention interventions AND Develop and examine the feasibility and acceptability of novel integrated interventions of biomedical and behavioral strategies that substantially reduce the likelihood of onward HIV transmission in these populations. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum period is 5 years.

Date: May 16, 2016; May 9, 2017; May 8, 2018, by 5:00 P.M.

National Institute of General Medical Sciences (NIGMS)

Go to site...

PI Lab Support Relevant to NIGMS Mission The Maximizing Investigators' Research Award (MIRA) is a grant to provide support for the program of research in an investigator's laboratory that falls within the mission of NIGMS.  For the purpose of this FOA, a program of research is the collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.  It is anticipated that this mechanism will:
• Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively;
• Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies;
• More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs;
• Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research;
• Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applications may request up to $750,000 direct costs per year. Applications may request a maximum project period of five years.

Date:May 17, 2017; January 17, 2018; May 17, 2018; January 17, 2019; May 17, 2019, by 5:00 PM

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Cancer Institute (NCI), National Eye Institute (NEI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Bioengineering, Biomedical, Multidisciplinary This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.     

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Date: May 18, 2016, September 13, 2016, May 18, 2017, September 13, 2017, May 8, 2018, September 13, 2018, by 5:00 P.M.

Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI)

Go to site...

Bioethics Scholars in LMIC nations The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare a number of individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request up to $230,000 direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. 

Date: May 18, 2017, May 17, 2018, by 5:00 PM

National Human Genome Research Institute (NHGRI)

Go to site...

Genomic Science The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research.  Each CEGS grant supports a multi-investigator, interdisciplinary team to develop innovative genomic approaches to address a particular biomedical problem.  A CEGS project will address a critical issue in genomic science or genomic medicine, proposing a solution that would be a very substantial advance.  Thus, the research conducted at these Centers will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff.  A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, or on a particular genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems and/or significantly furthering the application of genomic knowledge, data and methods towards clinical applications.  Exploiting its outstanding scientific plan and team, each CEGS will nurture genomic science at its institution by facilitating the interaction of investigators from different disciplines, and by providing training to new and experienced investigators, it will expand the pool of highly-qualified professional genomics scientists and engineers.

The NHGRI anticipates supporting not more than approximately ten CEGS projects at any one time and therefore not more than two awards will generally be made in any given year. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received, and the existing investment in the program. Although the financial plans of NHGRI provide support for this program, awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request up to $1.75 million direct costs for any year for continuing operations (e.g., personnel, standard laboratory equipment, supplies, travel, consortia, and other expenses). Inflationary adjustments will not be allowed. Many applications will not need to request the maximum budget and the size and duration of the awards will vary because the nature and scope of research programs will vary. Because of the unusual nature of these Centers, there may be a need to acquire specialized equipment. Funds for such specialized equipment may be requested in excess of the $1.75 million operating limit if well justified. Specialized equipment in excess of $500,000 over the life of the grant will generally not be permitted. A  CEGS grant application may request up to five years of support. The total length of support for any Center under this program will not exceed ten years.

Date: May 23, 2017; May 21, 2018; May 20, 2019, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

Underrepresented Students in Biomedical Research The Maximizing Access to Research Careers (MARC) Undergraduate Student Training in Academic Research (U-STAR) program is designed to provide structured training programs to prepare high-achieving, underrepresented students for doctoral programs in biomedical research fields. Programmatic activities should include authentic research experiences, academic enhancements, skills development, and mentoring. The long-term goal of the program is to enhance the pool of underrepresented students earning baccalaureate and Ph.D. degrees in biomedical research fields and ultimately to contribute to the diversification of the nation's scientific workforce.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: May 24, 2017; May 24, 2018, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Mentoring Networks The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on     Mentoring Activities and in particular, mentoring networks. Networks may be national or regional.  All proposed networks should provide significant new opportunities, and should comprise efforts substantially beyond any ongoing mentoring, networking, or research education within academic programs, institutions, or pre-existing networks; or educational collaborations among institutions.  Participants in proposed mentoring networks are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty.  Proposed networks are expected to enhance the participants' professional development and to foster their career trajectory towards independent mental health research. Proposed programs are thus expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIMH Strategic Plan.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets may not exceed $200,000 in direct costs annually and are expected to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum period is 5 years.

Date: May 24, 2017; May 24, 2018; May 24, 2019, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Research Experiences, Courses for Skill Development The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIMH R25 program is to support educational activities that will help recruit and retain individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Courses for Skills Development. Specifically, this FOA will support research-oriented experiences and activities designed to develop, maintain, and expand the abilities of psychiatry residents in areas relevant to the mission of NIMH. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets may not exceed $200,000 in direct costs annually and are expected to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Date: May 24, 2017; May 24, 2018; May 24, 2019, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Courses for Skill Development The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical mental health-related research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on  Courses for Skills Development. Proposed short courses are expected to facilitate the development of a sophisticated cadre of investigators with the requisite scientific research skills to advance the mission of the NIMH. Each short course is expected to include both didactics and hands-on research experiences.  Participants are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets may not exceed $200,000 in direct costs annually and are expected to reflect actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum period is 5 years.

Date: May 24, 2017; May 24, 2018; May 24, 2019, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical, Behavioral and Clinical Research The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and courses for skills development. Applicants should directly address how the set of activities will enhance the diversity of the biomedical, behavioral and clinical research workforce by discussing 1) the rationale underlying the balance of effort and resources dedicated to each activity; 2) how the three activities integrate; and 3) objective indicators that can measure the effectiveness of the program.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Date: May 25, 2016; May 25, 2017; and May 25, 2018, by 5:00 P.M.

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical Research The Maximizing Access to Research Careers (MARC) Undergraduate Student Training in Academic Research (U-STAR) program is designed to provide structured training programs to prepare high-achieving, underrepresented students for doctoral programs in biomedical research fields. Programmatic activities should include authentic research experiences, academic enhancements, skills development, and mentoring. Institutions eligible for MARC U-STAR grants are those with significant enrollments of honors students from groups underrepresented in the biomedical sciences. The long-term goal of the program is to  enhance the pool of underrepresented students earning baccalaureate and Ph.D degrees in biomedical research fields and ultimately to contribute to the diversification of the nation's scientific workforce.

The Maximizing Access to Research Careers (MARC) Undergraduate Student Training in Academic Research (U-STAR) program is designed to provide structured training programs to prepare high-achieving, underrepresented students for doctoral programs in biomedical research fields. Programmatic activities should include authentic research experiences, academic enhancements, skills development, and mentoring. Institutions eligible for MARC U-STAR grants are those with significant enrollments of honors students from groups underrepresented in the biomedical sciences. The long-term goal of the program is to  enhance the pool of underrepresented students earning baccalaureate and Ph.D degrees in biomedical research fields and ultimately to contribute to the diversification of the nation's scientific workforce.

Date: May 25, 2016; May 25, 2017; May 25, 2018, by 5:00 P.M.

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical, Behavioral, and Clinical Research The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and courses for skills development. Applicants should directly address how the set of activities will enhance the diversity of the biomedical, behavioral and clinical research workforce by discussing 1) the rationale underlying the balance of effort and resources dedicated to each activity; 2) how the three activities integrate; and 3) objective indicators that can measure the effectiveness of the program.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.  Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Date: May 25, 2017 and May 25, 2018, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH)

Go to site...

Neurosciences Training, Nervous System Function The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. . JSPTPN programs are intended to be two years in duration, and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare individuals for careers in neuroscience that will have a significant impact on our understanding of nervous system function and the health-related research needs of the nation.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. Grantees are expected to be familiar with and comply with applicable cost policies and the NRSA Guidelines (NIH Grants Policy Statement - Institutional Research Training Grants). Funds may be used only for those expenses that are directly related to and necessary for the research training and must be expended in conformance with OMB Cost Principles, the NIH Grants Policy Statement, and the NRSA regulations, policies, guidelines, and conditions set forth in this document.

Date: May 25, 2017; May 25, 2018; May 25, 2019, by 5:00 PM

National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Go to site...

Cancer Image Observers, Cancer Detection and Diagnosis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: May 30, 2017; September 26, 2017; May 30, 2018; September 26, 2018; May 30, 2019; September 26, 2019, by 5:00 PM

National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Go to site...

Cancer Image Observers, Cancer Detection and Diagnosis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: May 30, 2017; September 26, 2017; May 30, 2018; September 26, 2018; May 30, 2019; September 26, 2019, by 5:00 PM

National Institute of Biomedical Imaging and Bioengineering (NIBIB) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Biomedical, Behavioral and Clinical Research The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIBIB-NICHD R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA encourages applications from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate Biomedical Engineering departments or other degree-granting programs with Biomedical Engineering tracks/minors. This FOA mainly targets undergraduate students but may also include first-year graduate students. Courses and programs that address innovative and/or groundbreaking development, multidisciplinary/interdisciplinary education, the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion are especially encouraged.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs of up to $20,000 per year may be requested.  Programs that include a clinical immersion program outside the academic year and lasting 6 to 10 weeks may request an additional $20,000 to cover participant costs, yielding a total of $40,000 in direct costs. Project durations of up to five years may be requested.

Date: May 31, 2016; May 31, 2017; May 31, 2018, by 5:00 P.M.

National Cancer Institute (NCI)

Go to site...

Quantitative Imaging (QI) Software Tools, Cancer Therapies This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed $300,000 in direct costs for each year of the UG3 phase and $500,000 (direct costs) for each year of the UH3 phase. The proposed project period for the initial development phase (UG3) award may not exceed 2 years. The total UG3/UH3 period of performance may not to exceed 5 years.

Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Quantitative Imaging (QI) Software Tools, Cancer Therapies This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed $500,000 (direct costs) for each proposed year. The maximum project period is 5 years.

Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020, by 5:00 PM

This Funding Opportunity Announcement (FOA) is developed as a Common Fund Initiative through the NIH Office of the NIH Director, Office of Strategic Coordination. The FOA will be administered by the National Center for Advancing Translational Sciences (NCATS) on behalf of the NIH.

Go to site...

Control of Organ Function by the Peripheral Nervous System The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Technologies to Understand the Control of Organ Function by the Peripheral Nervous System. This NIH Funding Opportunity Announcement (FOA) solicits applications to develop new and/or enhance existing tools and technologies to facilitate the progress of other components of the SPARC program. The scope encompasses a wide range of capabilities, spanning the fields of photonics, systems engineering, virology and genomics, device design and manufacture, surface chemistry, tissue engineering, neural interfacing, biomarker sensing, and more.  The specific tools and technology priorities will vary for each receipt date listed in the companion OT1 pre-application funding opportunity (See RM-17-009 and  https://commonfund.nih.gov/sparc/FOApriorities).



NIH anticipates funding up to 20 awards through this FOA, corresponding to a total of approximately $10M in total costs in 2017, $6M in 2018 and $4M in 2019. While there is no limit, awards resulting from this FOA are expected to range between $250,000 and $5,000,000 direct costs per year. Awards are expected to be three years or less in duration, with the opportunity for additional funding. 

Date: New and resubmission applications are accepted on the date specified in the Invitation to Submit after successful competition of the corresponding OT1 pre-application (See RM-17-009) and must be submitted by 5:00 PM local time of the applicant.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

Multi-Level Physical Activity Intervention Programs  The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. 



NIH anticipates funding up to 20 awards through this FOA, corresponding to a total of approximately $10M in total costs in 2017, $6M in 2018 and $4M in 2019. While there is no limit, awards resulting from this FOA are expected to range between $250,000 and $5,000,000 direct costs per year. Awards are expected to be three years or less in duration, with the opportunity for additional funding. 

Date: New applications: February 16, 2018; October 16, 2018; June 16, 2019; February 16, 2020; October 16, 2020, by 5:00 PM local time of applicant organization. Resubmission applications: March 16, 2018; November 16, 2018; July 16, 2019; March 16, 2020; November 16, 2020, by 5:00 PM

National Heart, Lung, and Blood Institute (NHLBI) 

Go to site...

 Biomedical or Biobehavioral Research relevant to NHLBI The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection; it will not support the collection of new data.

The R21 phase may not exceed $275,000 in direct costs for the 2-year project period, with no more than $200,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed $750,000 in direct costs for the 3-year project period, with no more than $250,000 in direct costs in any single year of the R33 phase. The scope of the proposed project should determine the project period. The maximum period of the combined R21 and R33 phases is 5 years, with up to 2 years for the R21 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

Date: New applications: February 24, 2017; February 23, 2018; February 22, 2019, by 5:00 PM; Resubmission Applications: October 30, 2017; October 30, 2018; October 30, 2019, by 5:00 PM

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

Multi-Level Physical Activity Intervention Programs  The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NHLBI intends to fund up to ten awards per year. Direct costs must be limited to $150,000 over a R21 two-year period, with no more than $75,000 in direct costs allowed in any single year. Applications exceeding this amount will not be reviewed. The total project period may not exceed 2 years.

Date: New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM local time of applicant organization. Resubmission applications: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020; November 5, 2020, by 5:00 PM

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

Multi-Level Physical Activity Intervention Programs  The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation.  This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM. Resubmission applications: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020; November 5, 2020, by 5:00 PM.

National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Go to site...

Imaging or Spectroscopic Technologies, Cancer Biology The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem. The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: New Dates March 1, 2017; June 7, 2017; October 3, 2017; March 1, 2018; June 7, 2018; October 3, 2018; March 1, 2019; June 7, 2019; October 3, 2019, by 5:00 PM

National Heart, Lung, and Blood Institute (NHLBI)

Go to site...

Clinical Trials relevant to NHLBI mission This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted in response to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the requested project award period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 1 year for the R61 phase and up to 4 years for the R33 phase.

Date: New, and Revision applications: February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019, by 5:00 PM 

National Heart, Lung, and Blood Institute (NHLBI)

Go to site...

Clinical Trials, Clinical Coordinating Center relevant to NHLBI mission This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-18-410). The objective of the Clinical Coordinating Center application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should include plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined budgets of the CCC and DCC will be used to determine whether the policy regarding direct costs of $500,000 or more in any year will be applied. The project period for the UG3 phase will be up to 1 year. The project period for the UH3 phase is expected to be 4 years. With strong justification, up to 6 years for the UH3 may be requested.

Date: New, Renewal and Revision Applications: February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019, by 5:00 PM

National Heart, Lung, and Blood Institute (NHLBI)

Go to site...

Clinical Trials, Clinical Data Coordinating Center relevant to NHLBI mission This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Clinical Coordinating Center (PAR-18-407). The DCC application must be specific for the clinical trial being proposed in the collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined budgets of the CCC and DCC will be used to determine whether the policy regarding direct costs of $500,000 or more in any year will be applied. The period of award is expected to be 5 years. Up to 7 years may be requested if strongly justified.

Date: New, Renewal and Revision Applications: February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019, by 5:00 PM

National Institute of Mental Health (NIMH)  

Go to site...

Protected Research Time The purpose of the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training is to support advanced research opportunities for exceptional individuals holding the MD/PhD degree who are early in their research careers and thereby help these individuals transition efficiently and effectively from the period of clinical training to the next stage of their research careers. This administrative supplement program will provide focused, protected research time for eligible individuals during residency and/or clinical fellowship. The proposed research experience must have the potential to contribute significantly to the candidate’s research career. Administrative supplements must support work within the scope of the original project. All applicants are encouraged to discuss potential requests with the NIMH prior to submission (see Section VII. Agency Contacts). 

Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. The project and budget periods must be within the currently approved project period for the existing parent award. The project period of the supplement may not exceed the duration of the candidate's clinical training period nor may it include any anticipated period of no-cost extension of the parent grant.

Date: NIMH accepts and reviews applications on a continuous basis until April 1 of each fiscal year. Applications received after April 1 will be considered for funding in the next fiscal year. Earlier submission is strongly encouraged. Applications for FY 18 funds should be submitted no later than April 1, 2018.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 

Go to site...

Human Development and Pathologies This Funding Opportunity Announcement (FOA) encourages grant applications aimed at the collection, identification, staging, and distribution of conceptual tissues for use in studies to understand the underlying developmental biology of normal and abnormal human development as well as human pathologies.  The objective of this FOA is to provide support for established resources that serve the research community. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Date: October 27, 2016, January 30, 2017, May 30, 2017, September 27, 2017, January 30, 2018, May 30, 2018, September 26, 2018, January 30, 2019, May 30, 2019, by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), Office of Behavioral and Social Sciences Research (OBSSR)

Go to site...

Behavioral Factors Related to Obesity Prevention and Treatment The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications to support the addition of measures of psychological and/or behavioral constructs or weight-related variables (e.g.; BMI, body composition) to existing or new research studies in humans with the goal of elucidating behavioral or psychological phenotypes that explain individual variability in weight trajectory or response to obesity prevention or treatment interventions. The intent is to support the addition of new measurement in domains other than those covered in the parent grant as a means of elucidating the behavioral and psychological factors that may explain individual differences in weight status.  For the purposes of this FOA, behavioral factors related to energy intake include overt actions/behavior (e.g.; objective observation of eating event including measures such as quantity, selection/quality, and speed of intake) and underlying psychological processes related to self-regulation of intake such as cognitive control, affective response, learning, and motivation. The rationale is that an improved understanding of the individual characteristics and processes that explain energy intake patterns can lead to better matching of individuals to prevention or treatment approaches and identify novel targets for more efficacious individual and population level approaches to weight management.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: October 28, 2016; February 28, 2017; June 28, 2017; February 28, 2018; June 28, 2018; February 28, 2019, by 5:00 PM

National Institute on Deafness and Other Communication Disorders (NIDCD)

Go to site...

Human Communication Disorders The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders.  For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Budgets for new applications are limited to $1,500,000/year direct cost (DC).  Renewal (type 2) grant applications may request budgets (DC) that are no greater than 10% above the budget of the last year of the existing grant or $2,000,000 whichever is less.  Annual budget increases should not exceed more than NIH allowances at the time of submission of the application. Salary levels in all years are limited to the NIH maximum rate.  Revision applications requesting an additional research component to an existing P50 are allowed, but may not exceed the terms of the parent award or the budgetary caps as described above. The maximum project period is 5 years.

Date: October 3, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

 

Biomedical Sciences: Cell Biology, Biophysics, Genetics, Developmental Biology, Pharmacology, Physiology, Biological Chemistry, Computational Biology, Technology Development and Bioinformatics The NIGMS Postdoctoral Research Associate (PRAT) Program’s overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. The research projects proposed should focus on NIGMS mission-related areas of basic biomedical science. These include cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged. The PRAT Program distinguishes itself by providing, in addition to the laboratory research experience, a structured training environment with extensive career development and networking opportunities planned and supported by this program.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Fellowship budgets are composed of stipends and travel allowance. Postdoctoral fellows may receive up to 3 years of support from the NIGMS PRAT fellowship.

Date: October 3, 2016; October 3, 2017; October 3, 2018, by 5:00 P.M.

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Administrative Supplements This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)

The NINDS intends to fund approximately 30-50 participants across the entire R25 program in FY2018. The direct cost of each supplement award is capped at 80% of the appropriate PGY salary for the requested participant for the duration of support between July 1 and June 30 of the fiscal year in which support is requested, plus associated fringe benefits, plus $2,000 for travel to meetings plus $1,000 for travel to an NINDS R25 workshop. If the participant is simultaneously enrolled in a PHD-granting program, up to $12,800 may also be requested for costs associated with research activities associated with both R25 participation and the degree-granting program. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. 

Date: October 31, 2017, October 31, 2018, October 31, 2019 by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Go to site...

October 31, 2017; March 2, 2018; June 29, 2018; October 30, 2018; March 1, 2019; June 28, 2019; October 31, 2019; March 3, 2020; and June 30, 2020, by 5:00 PM  The NIDDK Central Repositories house valuable samples and data from numerous major clinical studies. This FOA allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at www.niddkrepository.org.  Applicants must provide information from the NIDDK Central Repositories documenting sample availability.

Funds are not awarded via the X01 mechanism. The maximum project period is 5 years.

Date: October 31, 2017; March 2, 2018; June 29, 2018; October 30, 2018; March 1, 2019; June 28, 2019; October 31, 2019; March 3, 2020; and June 30, 2020, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Adverse Drug Reactions This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: October 4, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Adverse Drug Reactions This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged.  

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 4 years.

Date: October 4, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Immunology Study Repository The goals of this Funding Opportunity Announcement (FOA) are to support the development of new or improved informatics tools and methods for the reuse of shared data in the immunology study repository, ImmPort; and to support secondary analyses of existing immunology datasets to address basic and clinical immunology questions.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in any single year. The maximum project period is two years.

Date: October 4, 2016; October 4, 2017; October 4, 2018, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Caregivers of Adult Cancer Patients This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018, April 11, 2019, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Caregivers of Adult Cancer Patients This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018, April 11, 2019, by 5:00 PM local time

National Cancer Institute (NCI)

Go to site...

Population-Level Strategies Targeting Cancer-Related Behaviors The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018; April 11, 2019, by 5:00 PM

National Institute on Deafness and Other Communication Disorders (NIDCD)

Go to site...

Hearing, Balance, Smell, Taste, Voice, Speech and Language Sciences The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIDCD anticipates funding 3 to 5 awards, corresponding to a projected total of $600,000 per year. Award budgets are composed of salary and other program-related expenses, as described below. Generally, the research experience shall span a contiguous period of six months to two years. 

Date: October 7, 2016; February 8, 2017; June 8, 2017; October 6, 2017; February 8, 2018; June 8, 2018; October 9, 2018; February 8, 2019; and June 6, 2019, by 5:00 PM

Diabetic Complications Consortium (DiaComp)

Go to site...

Diabetic Foot Ulcers The goal of the NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is to advance the study of diabetic complications and promote communication and collaboration between investigators involved in complications research by supporting scientific meetings and funding new research activities. The purpose of this Pilot Program is to adapt and evaluate emerging techniques focused on defining cell types and subtypes  and their three-dimensional context to the study of diabetic foot ulcers. This will be accomplished by funding pilot studies to conduct key establishing experiments that will be necessary to inform any future construction of an unbiased atlas of diabetic skin and foot ulcers. Pilot projects will be composed of multidisciplinary teams that consist of partnerships between: 1) clinical scientists with experience in diabetic foot ulcer biology and access to fresh human biopsies/surgical material for analysis, and 2) investigators with expertise in applying a diverse set of agnostic, medium- to high-throughput technologies with single cell-resolution to the systematic exploration of the cellular diversity of human tissues (e.g., CLARITY combined with highly multiplexed profiling of proteins and/or RNAs, imaging mass cytometry, etc.) or human tissue-derived cells (e.g., RNAseq, Dropseq, ATACseq, etc.). 

Applicants may request up to $750,000 Total Costs (direct + indirect costs) to support a project period of up to 2 years. 

Date: Proposals are due January 25th, 2018 for an April 30th, 2018 start date

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR) 

Go to site...

Research Activities for Early Stage Careers of Independent Clinical Researchers The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers.  This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program.  In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

For the transition award (R00), applicants can request direct costs of up to $499,000 per year.  This amount includes salaries, fringe benefits, and research costs.  Indirect costs will be reimbursed at the extramural sponsoring institution’s indirect cost rate. The R00 transition award is for up to 5 years.

Date: Rolling receipt dates: September 25, 2017 - January 7, 2018; January 25, 2018 - May 7, 2018; May 25, 2018 - September 7, 2018; September 25, 2018 - January 7, 2019; January 25, 2019 - May 7, 2018; May 25, 2019 - September 7, 2019; September 25, 2019 - January 7, 2020; January 25, 2020 - May 7, 2020; , by 5:00 PM 

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Clinical Trials This Funding Opportunity Announcement (FOA) encourages applications for implementation of investigator-initiated, non-high-risk clinical trials.  The trials should be hypothesis-driven, related to the research mission of the NIAID and considered a high priority by the Institute.  Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (http://www3.niaid.nih.gov/about/whoWeAre/planningPriorities/). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation (R01) Grant application.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Clinical Trials This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (http://www3.niaid.nih.gov/about/whoWeAre/planningPriorities/). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Clinical Trials This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID.  This program provides support for hypothesis-driven, milestone-driven clinical trials.  Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies.  High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program.  However, not more than one clinical trial should be proposed within each application.  The NIAID has a robust infrastructure for conducting clinical studies that includes independently managed resources provided through grants, cooperative agreements, and contracts, as well as resources that are integrated within existing NIAID-supported clinical trial networks.  Proposed clinical trials may use NIAID’s independent infrastructure for clinical studies, however, support will not be provided for studies that propose to use dedicated resources that are part of a NIAID-supported clinical trial network.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.  With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II). NIH has received a waiver from SBA, as authorized by the statute, to exceed the hard cap for specific topics. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.  Durations up to 1 years for Phase I and up to 3 years for Phase II may be requested.

Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Clinical Trials This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (http://www3.niaid.nih.gov/about/whoWeAre/planningPriorities/). 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

CounterACT Program, Chemical Threats The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans.  It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.    

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. For most applications within the scope of this FOA, the expected direct cost for individual awards is $300,000-$500,000 per year. The maximum project period for an application submitted in response to this funding opportunity may not exceed five years.

Date: September 13, 2016; September 12, 2017; September 11, 2018, by 5:00 P.M.

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

CounterACT Program, Chemical Threats The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies must result in the identification of at least one lead compound ready for advanced therapeutic development. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-16-XXX). The scope of this FOA encompasses Technical Readiness Level (TRL) 3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.    

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The budget for direct costs for the three year project period may not exceed $900,000. No more than $300,000 direct cost may be requested in any single year. The requested budget will need to reflect the actual needs of the proposed project. The maximum project period for an application submitted in response to this funding opportunity may not exceed three years.   

Date: September 13, 2016; September 12, 2017; September 11, 2018, by 5:00 P.M.

National Institute of Neurological Disorders and Stroke (NINDS) National Eye Institute (NEI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

 Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence  The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-16-331). The scope of this FOA encompasses Technical Readiness Level (TRL) 3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The budget for direct costs for the three year project period may not exceed $900,000. No more than $300,000 direct cost may be requested in any single year. The requested budget will need to reflect the actual needs of the proposed project. The maximum project period for an application submitted in response to this funding opportunity may not exceed three years.

Date: September 13, 2016; September 12, 2017; September 11, 2018, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

 Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence  The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans.  It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. For most applications within the scope of this FOA, the expected direct cost for individual awards is $300,000-$500,000 per year. Many applications will not need to request the maximum budget and the size and duration of the awards will vary depending upon the nature and scope of research programs. The maximum project period for an application submitted in response to this funding opportunity may not exceed five years.

Date: September 13, 2016; September 12, 2017; September 11, 2018, by 5:00 PM

National Cancer Institute (NCI)

Go to site..

Cancer Phenotype The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Date: September 14, 2016; March 1, 2017; September 6, 2017; March 7, 2018; September 6, 2018; March 6, 2019, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Physics/Mechanics of Embryonic Development This Funding Opportunity Announcement (FOA) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this FOA is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. The total project period may not exceed two years.

Date: September 19, 2016; September 19, 2017; September 19, 2018, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Physics/Mechanics of Embryonic Development This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations that propose to advance our knowledge in the area of the physics and mechanics of embryonic development. Applicants should propose hypothesis-driven developmental research with the prospect of gaining new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. Investigators are encouraged to explore approaches and concepts new to the area of developmental tissue mechanics, and use newly developed techniques superior to the ones currently used in the field. It should be noted that applications submitted to this R01 FOA should have sufficient preliminary data to substantiate the validity of the proposed research and feasibility of new technologies or tools.  

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The budget may not exceed $500,000 Direct Costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: September 19, 2016; September 19, 2017; September 19, 2018, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical, Behavioral and Clinical Research The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIGMS  R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.  To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development,  Research Experiences, and Curriculum or Methods Development. A proposed program must include each activity and describe how they will be integrated. The Bridges to Baccalaureate Program is intended to provide these activities to community college students to increase transfer and retention to BS graduation in biomedical sciences. This program requires partnerships between community colleges or other two-year post-secondary educational institutions granting the associate degree with colleges or universities that offer the baccalaureate degree. Applicants should directly address how the set of activities will complement and/or enhance the training of a workforce to meet the nation’s biomedical and clinical research needs by discussing 1) the rationale underlying the balance of effort and resources dedicated to each activity; 2) how the activities integrate; and 3) objective indicators that can measure the effectiveness of the program. Recruitment and retention plans are required elements of the program.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The budget may not exceed $500,000 Direct Costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $300,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: September 19, 2016; September 19, 2017; September 19, 2018, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical, Behavioral and Clinical Research The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIGMS  R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.  To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences. The Bridges to Doctorate Program is intended to provide these activities to master's level students to increase transition to and completion of PhDs in biomedical sciences. This program requires partnerships between master's degree-granting institutions with doctorate degree-granting institutions.  Applicants should directly address how the set of activities will complement and/or enhance the training of a diverse workforce that also meets the nation’s biomedical and clinical research needs by discussing 1) the rationale underlying the balance of effort and resources dedicated to each activity; 2) how the activities integrate; and 3) objective indicators that can measure the effectiveness of the program. A program application must include each activity, and describe how they will be synergized to make a comprehensive program. Additionally, recruitment and retention plans are expected as part of the application.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $300,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: September 25, 2016; September 25, 2017; September 25, 2018. If the date falls on a week-end, the application is due the next business day, by 5:00 P.M.

National Institute on Drug Abuse (NIDA)

Go to site...

Drug Abuse and Addiction NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: September 26, 2017; September 26, 2018, September 26, 2019, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Food and Agriculture (USDA-NIFA)

Go to site...

 Farm Animal Models that mimic Human Developmental, Physiological and Etiological Processes The purpose of this interagency Funding Opportunity Announcement (FOA) is to invite the submission of grant applications that utilize agriculturally important domestic animal species to improve human health through the advancement of basic and translational research deemed highly relevant to both agricultural and biomedical research. This initiative is designed to facilitate and encourage comparative medicine research studies through the careful selection and refinement of farm animal models that mimic human developmental, physiological and etiological processes to better understand the biology of fertility and infertility, normal and abnormal metabolism, developmental origin of diseases, and improve prevention and treatment of infectious diseases in both human and agriculturally important domestic animals. The anticipated outcomes include both the elucidation of fundamental information relevant for the improvement of human health and an increase in food animal production and improvement in animal health and product quality. It is envisioned that each application will address mission-relevant areas of both agencies.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. It is the intention of NIH and USDA-NIFA to independently fund grants, and funding in subsequent years will be the responsibility of the agency awarding the grant. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: September 27, 2016; September 27, 2017; September 27, 2018, by 5:00 PM

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical Research Infrastructure The National Institute of General Medical Sciences (NIGMS) of the NIH invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for National Institutes of Health (NIH) individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in IDeA states. 

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The annual budgets must not exceed $1.5 million in direct costs, excluding facilities and administrative (F&A) costs on consortium arrangements. The project period is limited to five years.

Date: September 28, 2016; September 28, 2017; and September 28, 2018, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Parkinson's Disease, Synucleinopathies The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research to discover human biomarkers in Parkinson’s disease and other Parkinsonian syndromes, as a component of the NINDS Parkinson’s Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as  Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically. A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Date: September 6, 2016; September 6, 2017; September 6, 2018, by 5:00 P.M.

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Immune Responses Induced by Mycobacterial Infections, Bacillus Calmette-Guérin Vaccine (BCG), or Mycobacterium Tuberculosis (Mtb) Vaccines  This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years.

Date: September 6, 2016; September 6, 2017; September 6, 2018, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Mentored Research Supporting Career Trajectory Towards Independent Research in the Mental Health of HIV/AIDS.     The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this National Institute of Mental Health (NIMH)  R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application may not exceed five years.

Date: September 7, 2018; September 7, 2019; September 7, 2020, by 5:00 PM

National Institute on Deafness and Other Communication Disorders (NIDCD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Language/Literacy Development of Dual Language Learners (DLLs) in USA The purpose of this FOA is to support investigator-initiated R01 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply by 5:00 PM

National Institute on Deafness and Other Communication Disorders (NIDCD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Language/Literacy Development of Dual Language Learners (DLLs) in USA The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations

The combined budget for direct costs for the two-year project period may not exceed $275,000 No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: Standard dates apply by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Go to site...

Clinical Trials relevant to NIDDK mission This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases.  Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Date:  Standard dates apply by 5:00 PM

National Center for Advancing Translational Sciences (NCATS)

Go to site...

Clinical Studies to Repurpose Existing Drugs or Biologics (Therapeutics)  This Funding Opportunity Announcement (FOA) invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase l trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/therapeutics/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use.

Application budgets need to reflect the actual needs of the proposed project. In a disease agnostic pool of applications, the budget for individual projects is highly dependent on the disease area and methods proposed. The budget is expected to be not more than $3,000,000 direct costs/year. The project period may be up to three years.

Date: Standard dates apply by 5:00 PM

National Heart, Lung, and Blood Institute (NHLBI)

Go to site...

Program Project applications relevant to NHLBI mission This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications.  The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also address implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which has an Early Stage Investigator as Project Leader.

New (Type 1) and Renewal (Type 2) applications must limit their budget request to $1,515,000 in direct costs (excluding first-tier subcontract Facilities and Administrative [F&A] costs) or less in each year. If an ESI-led Project is included and the application contains a minimum of four Projects, New (Type 1) applications must limit their budget request to $1,765,000 in direct costs (excluding first-tier subcontract Facilities and Administrative [F&A] costs) in each year (with a minimum of $250,000 per year in direct costs for the ESI-led Project). The scope of the proposed program should determine the project period. The maximum program period is 5 years.

Date: Standard dates apply by 5:00 PM

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Alcohol-induced Effects on Tissue Injury and Repair This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

Date: Standard dates apply by 5:00 PM

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Alcohol-induced Effects on Tissue Injury and Repair This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Research Grant Award (R21) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage.

The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is two years.

Date: Standard dates apply by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Complex Brain Disorders, Neuronal Function This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.  The present announcement seeks R01 applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years.   

Date: Standard dates apply, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Complex Brain Disorders, Neuronal Function This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.  The present announcement seeks R21 applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 2 years.   

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA), National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR)

Go to site...

HIV and Aging This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR)

Go to site...

HIV and Aging This FOA encourages exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Human Genome Research This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC)

Go to site...

Human Genome Research This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators.  Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.  This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Human Genome Research This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration. Longer project periods should be well justified.  Additional consideration for longer projects may be given to new or early stage investigators.  All applicants are strongly encouraged to discuss project length with Scientific/Research Staff prior to submission.

Date: Standard dates apply, by 5:00 PM

National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA)

Go to site...

Cell-Based Chemical Probes This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.  

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 3 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Secondary Analyses of Existing Alcohol Research Data  This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems.  Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Secondary Analyses of Existing Alcohol Research Data 

This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems.  Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.

 

Application budgets are limited to $50,000 in direct costs per year. The total project period may not exceed two years.

Date: Standard dates apply, by 5:00 PM

Agency for Healthcare Research and Quality (AHRQ)

Go to site...

Research Training Fellowship The purpose of this individual postdoctoral research training fellowship is to enhance the research training of promising postdoctoral candidates who have the potential to become productive, independent investigators in health services research, with a research interest in areas and priorities relevant to the mission of AHRQ.

Award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below. Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

SBIR Phase IIB relevant to NINDS mission This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH’s SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $1,500,000 for Phase II for specific topics. Durations up to 3 years for Phase II may be requested.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Small Business Innovation Research (SBIR) relevant to NINDS mission This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects requiring approval from a Federal regulatory agency or for those projects developing complex research tools. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NIH’s SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $1,000,000 for Phase II awards.  With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $1,500,000 for Phase II for specific topics. Durations up to 3 years for Phase II may be requested.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI)

Go to site...

Genomics NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years, but given how quickly the field is evolving, in order to ensure that the research is addressing the most current issues, many projects that are funded will be no more than 3 years in duration.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

Social Genomics approach to Chronic Wound Risk, Presence, Progression, and Healing The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

Social Genomics approach to Chronic Wound Risk, Presence, Progression, and Healing The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life.

The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Follow-Up to Abnormal Screening Tests for Breast, Cervical, Colorectal, or Lung Cancers This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

HIV-Related Health Outcomes The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

HIV-Related Health Outcomes The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)

Go to site...

Organ-Specific Cancer This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Approximately four to eight SPORE awards per year are anticipated. Applicants may request a maximum of $1,400,000 direct costs/year, which excludes third party indirect costs. Applications that include one or more qualified Early Detection, Prevention, or Population Science (qualified EPPS) project(s) may request up to an additional $120,000 direct costs/year to support this project(s), if appropriate. The maximum budget period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA)

Go to site...

Osteoarthritis Initiative (OAI) This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images.  This FOA seeks to expand the use of these resources by investigators in the broader research community.  The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources.

The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA)

Go to site...

Osteoarthritis Initiative (OAI) This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images.  This FOA seeks to expand the use of these resources by investigators in the broader research community.  The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA)

Go to site...

Technologies to Monitor the Daily Activities of Alzheimer's Disease Patients/At-Risk Individuals This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

Budgets up to $350,000 total costs per year for Phase I and up to $2,000,000 total costs per year for Phase II may be requested. According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II. 

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA)

Go to site...

Technologies to Monitor the Daily Activities of Alzheimer's Disease Patients/At-Risk Individuals This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

Budgets up to $350,000 in total costs per year for Phase I and up to $2,000,000 in total costs per year for Phase II may be requested. According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II.

Date: Standard dates apply, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Psychiatric Disorders in areas of Unmet Medical Need The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development

Application budgets are not limited but need to reflect the actual needs of the proposed project. For pharmacologic trials, the total project period may not exceed one year for FIH or Phase Ib and 3 years for PoC trials. Only applications that include both FIH and PoC trials may request 4 years. The duration of the device trial(s) must be appropriate for the proposed project, with a maximum of four years. NIMH encourages shorter project periods.

Date: Standard dates apply, by 5:00 PM

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Primary Immunodeficiency Diseases This Funding Opportunity Announcement (FOA) will support small grants on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.   The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA.

A budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 over two years). The project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Primary Immunodeficiency Diseases This Funding Opportunity Announcement (FOA) will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.

Direct costs are limited to $275,000 over the two-year project period, with no more than $200,000 in direct costs allowed in any single year. The project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Ethical, Legal and Social Implications (ELSI) of Human Genome Research This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration.  Longer project periods should be well justified.  Additional consideration for longer projects may be given to new or early stage investigators.  All applicants are strongly encouraged to discuss project length with Scientific/Research Staff prior to submission.

Date: Standard dates apply, by 5:00 PM 

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC)

Go to site...

Ethical, Legal and Social Implications (ELSI) of Human Genome Research This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators.  Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.  This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date Standard dates apply, by 5:00 PM 

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Ethical, Legal and Social Implications (ELSI) of Human Genome Research This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project, with no more than $200,000 in direct costs in a single year. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Pregnancy among Women with Disabilities This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities.  Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families.  Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Date: Standard dates apply, by 5:00 PM 

National Institute of Nursing Research (NINR), National Institute of Mental Health (NIMH)

Go to site...

Depressive Symptoms, Sudden Onset Acute Illness The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.

The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

National Institute of Nursing Research (NINR), National Institute of Mental Health (NIMH)

Go to site...

Depressive Symptoms, Sudden Onset Acute Illness The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM 

National Institute of General Medical Sciences (NIGMS)

Go to site...

Biomedical Research The goal of the National Institute of General Medical Sciences (NIGMS)-sponsored Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool of well-trained scientists available to address the Nation's biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. Grantees are expected to be familiar with and comply with applicable cost policies and the NRSA Guidelines (NIH Grants Policy Statement - Institutional Research Training Grants). Funds may be used only for those expenses that are directly related to and necessary for the research training and must be expended in conformance with OMB Cost Principles, the NIH Grants Policy Statement, and the NRSA regulations, policies, guidelines, and conditions set forth in this document. Awards may be for project periods up to five years in duration and are renewable.

Date: Standard dates apply, by 5:00 PM 

National Cancer Institute (NCI)

Go to site...

Commercial Development of Novel Cancer-Relevant Technologies This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.


NCI intends to fund an estimate of 10 awards, corresponding to a total of $2-3 million, for fiscal year 2018. Future year amounts will depend on annual appropriations. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II.

Date: Standard dates apply, by 5:00 PM 

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Neurological Emergencies This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum requested project period cannot exceed 5 years but the actual funded project period is dependent on reaching specific milestones as described in this FOA.

Date: Standard dates apply, by 5:00 PM 

National Center for Complementary and Integrative Health (NCCIH)

Go to site...

Fundamental Science of Mind and Body Approaches This funding opportunity announcement (FOA) encourages exploratory /developmental research grant applications (R21) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

National Center for Complementary and Integrative Health (NCCIH)

Go to site...

Fundamental Science of Mind and Body Approaches This Funding Opportunity Announcement (FOA) encourages research grant applications (R01) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM 

National Institutes of Health (NIH)

Go to site...

Education and Health: New Frontiers (R21) The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Date: Standard dates apply

National Institutes of Health (NIH)

Go to site...

Education and Health: New Frontiers (R03) The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

The combined budget for direct costs for the two year project period may not exceed $100,000. No more than $50,000 in direct costs may be requested in any single year.

Date: Standard dates apply

National Institutes of Health (NIH)

Go to site...

Education and Health: New Frontiers (R01) The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply

National Institute on Aging (NIA)

Go to site...

Aging The NIA is committed to identifying effective treatments for diseases and conditions associated with aging and to ascertaining the associated health outcomes by supporting robust, well-planned and designed, and well-executed clinical trials and clinical research projects.

Total direct costs are limited to $450,000 over a three-year period, with no more than $225,000 in direct costs allowed in any single year.

Date: Standard dates apply

National Institutes of Health (NIH) (NIEHS) (NINR)

Go to site...

Community Exposures to Environmental Contaminants  This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard dates apply

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Go to site...

Accelerating Research on Intervertebral Disc (ARID) (R01) The purpose of this Funding Opportunity Announcement (FOA) is to encourage the submission of grant applications proposing studies on basic biology of the intervertebral disc.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard dates apply

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Go to site...

Accelerating Research on Intervertebral Disc (ARID) (R21) The purpose of this Funding Opportunity Announcement (FOA) is to encourage the submission of exploratory/developmental grant applications proposing studies on basic biology of the intervertebral disc.

The combined budget for direct costs for the two year project period may not exceed $275,000.

Date: Standard dates apply

National Institutes of Health (ORIP), (NIAD), (NIDCR), (NIEHS)

Go to site...

Animal Stem Cells (R01) This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.  

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard dates apply

National Institutes of Health (ORIP), (NIAD), (NIDCR), (NIEHS)

Go to site...

Animal Stem Cells (R21) This FOA encourages Exploratory/Developmental Research grant (R21) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.

The combined budget for direct costs for the two year project period may not exceed $275,000. 

Date: Standard dates apply

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Multidisciplinary Research in Vulvodynia (R21) The purpose of this Funding Opportunity Announcement (FOA) is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research.

The combined budget for direct costs for the two year project period may not exceed $275,000.No more than $200,000 may be requested in any single year.

Date: Standard dates apply

National Institute on Aging (NIA)

Go to site...

Aging and Geriatric Research The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution.

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years.

Date: Standard dates, by 5:00 PM

National Institutes of Health (NIH)

Go to site...

Mobile/wireless Health Technologies Invites revision applications from investigators and institutions/organizations with active NIH-supported research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile/wireless tools to validate these tools for measurement and intervention delivery. 

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard dates apply

National Institutes of Health (NIH), NIMH, NIAAA, NIDA

Go to site...

Nervous System Disorders. Encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard Due Dates Apply

National Institutes of Health (NIH), NIMH, NIAAA, NIDA

Go to site...

Drug Discovery For Nervous System Disorders (R21) Encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders.

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Date: Standard Due Dates Apply

National Institutes of Health (NIH), NIDDK

Go to site...

Intestinal Stem Cell Encourages applications to conduct ancillary studies to the NIDDK Intestinal Stem Cell Consortium (ISCC).

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Date: Standard Due Dates Apply

National Institutes of Health (NIH), NIDDK

Go to site...

Brain To promote progress in development of new technologies as well as in theory and data analysis, the BRAIN Initiative encourages collaborations between neurobiologists and researchers with expertise in statistics, physics, mathematics, engineering, and computer science, and NIH welcomes applications from investigators in these disciplines.

The direct costs are limited to $125,000 per year

Date: Standard Due Dates Apply

National Institute on Drug Abuse (NIDA)

Go to site...

medications to prevent and treat opioid use disorders (OUD) and overdose  The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. 

NIDA intends to commit $10M in each fiscal year to a sufficient number of meritorious applications. NIDA intends to commit $10M in each fiscal year and to fund 3 to 4 grants per fiscal year. Application budgets are limited to $3 million direct costs per year and they need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

Date: Applications will be accepted on a rolling basis, beginning on January 25, 2018

National Institute on Drug Abuse (NIDA)

Go to site...

HIV prevention and treatment for PWID This FOA supports developing and testing implementation approaches that scale-up evidence based interventions in low to middle income countries among PWID where they form an important component of the national HIV epidemic, including countries where PWID are a relatively emergent population for HIV cases. Projects need to align with national HIV/AIDS plans and provide models for large scale implementation, including QA/QC systems. Collaboration with local or regional PEPFAR and Global Fund programs is encouraged. Recently introduced syringe services and drug treatment settings should be leveraged as well as new health financing systems, criminal justice reforms or other local innovations that can be used to expand HIV prevention and treatment for PWID. Collaboration with NIH initiatives such as IeDEA (NIH’s cohort of cohorts co-funded by NIDA) and existing NIDA-funded projects is encouraged.

NIDA intends to commit $3,000,000 in FY 2018 to fund 3-5 awards, and NIDA intends to commit $1,500,000 in FY 2019 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: April 13, 2018 and November 15, 2018, by 5:00 PM

National Institute on Drug Abuse (NIDA)

Go to site...

HIV-1 pathogenesis in individuals with substance use disorders (SUDs) The goal of this Funding Opportunity Announcement [FOA] is to support research that will define and validate a set(s) of molecular biomarkers and/or bio-signatures indicating the degree of loss of functional reserve, or of resilience of the host defense mechanisms, at different phases of HIV-1 pathogenesis in individuals with substance use disorders (SUDs).

NIDA intends to commit $3,000,000.00 in FY 2018 to fund 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: April 17, 2018 , by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

recording and/or stimulating devices to treat nervous system disorders and better understand the human brain The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device.  This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. Individuals, institutions or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or RFA-NS-18-023.

The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The duration of the UG3 phase cannot exceed 4 years and the total duration of the UG3/UH3 phases combined may not exceed 5 years.

Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM 

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

recording and/or stimulating devices to treat nervous system disorders and better understand the human brain The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain.  The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study).  Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device.  This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.  The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.

NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Applications should rarely exceed $1,000,000 in total cost per year during the SBIR Phase I and $1,500,000 in total costs per year during the SBIR Phase II. Durations up to 2 years for SBIR Phase I and up to 3 years for SBIR Phase II may be requested.

Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM 

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

recording and/or stimulating devices to treat nervous system disorders and better understand the human brain The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).  Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.  The clinical trial should provide data to answer key questions about the function or final design of a device.  This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.  The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device .Individuals, institutions or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-18-021 or this FOA.

The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards.  Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year. The total duration may not exceed 5 years.

Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM 

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

pathobiology, pathophysiology, and neuropathology of neurological disorders This FOA supports hypothesis-driven mechanistic clinical trial studies in basic and/or translational discovery research in healthy human subjects and in the pathobiology, pathophysiology, and neuropathology of neurological disorders. The goal is to address basic questions and to interrogate concepts in biology, behavior, and pathophysiology that will provide insight into understanding neurological disorders.  Such studies may seek to understand a biological or behavioral process, or the mechanism of action of an intervention. NINDS supports biomarker studies that may provide information about physiological function, target engagement of novel therapeutics, and/or mechanisms of therapeutic responses. The submitted studies are defined as clinical trials (NOT-OD-15-015) but do not seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions. preventive, therapeutic, and services interventions. Such designs should be submitted to an NINDS clinical trial-specific funding announcement (listed on the NINDS website at https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research). Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

early career investigators from underrepresented groups in neuroscience research The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groupsin neuroscience research.  This opportunity provides postdoctoral fellows from underrepresented groupswith strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position.  Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA PAR-18-468). 

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Curriculum or Methods Development The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The maximum budget is $150,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Courses for Skills Development The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The maximum budget is $300,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

Research Experiences The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The maximum budget is $300,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

reducing the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system.  Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. This FOA is published in parallel to a companion R34 FOA (PAR-18-228) supporting pilot studies in preparation for the larger-scale studies described here.   

NIMH intends to commit $1.3 million dollars for this and the companion R34 announcement (PAR-18-228) to fund 4 awards in this initiative. Application budgets are limited to $500,000 direct costs   per budget year and should reflect the actual needs of the proposed project. The total project period for applications submitted in response to this FOA may not exceed five years.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

pathobiology, pathophysiology, and neuropathology of neurological disorders This FOA supports hypothesis-driven mechanistic clinical trial studies in basic and/or translational discovery research in healthy human subjects and in the pathobiology, pathophysiology, and neuropathology of neurological disorders. The goal is to address basic questions and to interrogate concepts in biology, behavior, and pathophysiology that will provide insight into understanding neurological disorders.  Such studies may seek to understand a biological or behavioral process, or the mechanism of action of an intervention. NINDS supports biomarker studies that may provide information about physiological function, target engagement of novel therapeutics, and/or mechanisms of therapeutic responses. The submitted studies are defined as clinical trials (NOT-OD-15-015) but do not seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions. preventive, therapeutic, and services interventions. Such designs should be submitted to an NINDS clinical trial-specific funding announcement (listed on the NINDS website at https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research).

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. NINDS anticipates that most Diversity Faculty K01 awards will be 5 year awards and applicants should propose a research plan that reflects the total project period (up to 5 years); however, if the year 3 administrative review determines that an investigator is not applying for appropriate research grants or making sufficient progress towards preliminary data for such a submission, the award may not be extended.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

early career investigators from underrepresented groups in neuroscience research The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA PAR-18-486). 

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. Initial budget period to be awarded is 3 years and a continuation for years 4 and 5 are contingent on administrative review by NINDS staff. NINDS anticipates that most Diversity Faculty K01 awards will be 5 year awards and applicants should propose a research plan that reflects the total project period (up to 5 years); however, if the year 3 administrative review determines that an investigator is not applying for appropriate research grants or making sufficient progress towards preliminary data for such a submission, the award may not be extended.

Date: Standard dates apply, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

fundamental questions in basic neuroscience The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related.

NINDS intends to fund up to 12 awards, corresponding to a total of $5.0 million for fiscal year 2019. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

neonatal and pediatric resuscitation The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices.  Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof.  It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

neonatal and pediatric resuscitation The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices.  Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies prospective randomized controlled trials, or any combinations thereof.  It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.

Application budgets are limited to $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...

systematic screening and treatment of depression in cancer patients The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Cancer Institute (NCI)

Go to site...
 

systematic screening and treatment of depression in cancer patients The purpose of this Funding Opportunity Announcement (FOA)is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

EOLPC health literacy This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

EOLPC health literacy This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Eye Institute (NEI)

Go to site...

visual system The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system.  Applications that will be supported may be either: Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA.  Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA.  Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA), National Center for Complementary and Integrative Health (NCCIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI)

Go to site...

palliative care in geriatric populations This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Go to site...

palliative care in geriatric populations This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and limited interventional studies where feasible for this R21 mechanism.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Dental and Craniofacial Research (NIDCR)

Go to site...

dental, oral and craniofacial health The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists.  This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-156).   

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 7 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Go to site...

exploratory/developmental research projects of interest to the NIBIB This FOA will support exploratory/developmental research projects of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

Application budgets may not exceed $275,000 direct costs over a maximum two-year funding period. No more than $200,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH)

Go to site...

synthetic biology for human health This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early Stage Investigators in Synthetic Biology are especially encouraged to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum award project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Eye Institute (NEI), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) 

Go to site...

novel neurotechnologies commercialization The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research.

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. Durations up to two years for Phase I and up to three years for Phase II may be requested.

Date: Standard dates apply, by 5:00 PM

National Eye Institute (NEI), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) 

Go to site...

novel neurotechnologies commercialization The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. Durations up to two years for Phase I and up to three years for Phase II may be requested.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site...

biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site..

biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: 
Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site...

self-management for health in chronic conditions The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

Community Engaged Research (CEnR) methodologies This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

Community Engaged Research (CEnR) methodologies This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site...

self-management for health in chronic conditions The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

symptom and genomic nursing science This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR)

Go to site...

decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.

Applicants may request up to $300,000 in direct for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site...

biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Date: Standard dates apply, by 5:00 PM

National Institute of Nursing Research (NINR), National Institute on Aging (NIA)

Go to site...

self-management for health in chronic conditions The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.

Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Date: Standard dates apply, by 5:00 PM